Krystal Biotech Stock Today

KRYS Stock  USD 251.29  2.07  0.82%   

Performance

Strong

 
Weak
 
Strong

Odds Of Distress

Tiny

 
High
 
Low
Krystal Biotech is selling for under 251.29 as of the 25th of December 2025; that is 0.82 percent decrease since the beginning of the trading day. The stock's lowest day price was 249.73. Krystal Biotech has a very small chance of experiencing financial distress in the next few years and had a strong performance during the last 90 days. The performance scores are derived for the period starting the 26th of September 2025 and ending today, the 25th of December 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
20th of September 2017
Category
Healthcare
Classification
Health Care
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. The company has 29 M outstanding shares of which 2.87 M shares are now shorted by private and institutional investors with about 8.98 trading days to cover. More on Krystal Biotech

Moving together with Krystal Stock

  0.76DMAC DiaMedica TherapeuticsPairCorr

Moving against Krystal Stock

  0.93PYC Physiomics PlcPairCorr
  0.87DRMA Dermata Therapeutics Buyout TrendPairCorr
  0.79AVH Avita MedicalPairCorr
  0.76VIVS VivoSim Labs, Symbol ChangePairCorr
  0.72VALN Valneva SE ADRPairCorr
  0.71DYAI Dyadic InternationalPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Krystal Stock Highlights

ESG Sustainability
Environmental
Governance
Social
President FounderSuma Krishnan
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.290.2752
Notably Up
Slightly volatile
Gross Profit Margin0.730.9309
Significantly Down
Pretty Stable
Total Current Liabilities107.1 M102 M
Sufficiently Up
Slightly volatile
Total Assets1.1 B1.1 B
Sufficiently Up
Slightly volatile
Total Current Assets779.1 M742 M
Sufficiently Up
Slightly volatile
Debt Levels
Krystal Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Krystal Biotech's financial leverage. It provides some insight into what part of Krystal Biotech's total assets is financed by creditors.
Liquidity
Krystal Biotech currently holds 7.26 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Krystal Biotech has a current ratio of 12.2, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Krystal Biotech's use of debt, we should always consider it together with its cash and equity.

Depreciation

7.05 Million
Krystal Biotech (KRYS) is traded on NASDAQ Exchange in USA and employs 275 people. Krystal Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.35 B. Krystal Biotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 29 M outstanding shares of which 2.87 M shares are now shorted by private and institutional investors with about 8.98 trading days to cover. Krystal Biotech currently holds about 425.56 M in cash with 123.42 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.58.
Check Krystal Biotech Probability Of Bankruptcy
Ownership Allocation
Krystal Biotech maintains a total of 29 Million outstanding shares. The majority of Krystal Biotech outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Krystal Biotech to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Krystal Biotech. Please pay attention to any change in the institutional holdings of Krystal Biotech as this could imply that something significant has changed or is about to change at the company. Also note that almost three million one hundred seventy-eight thousand one hundred twenty-eight invesors are currently shorting Krystal Biotech expressing very little confidence in its future performance.
Check Krystal Ownership Details

Krystal Stock Institutional Holders

InstituionRecorded OnShares
Goldman Sachs Group Inc2025-06-30
530.4 K
Dimensional Fund Advisors, Inc.2025-06-30
505.9 K
Norges Bank2025-06-30
282.7 K
T. Rowe Price Associates, Inc.2025-06-30
261.4 K
Northern Trust Corp2025-06-30
251.4 K
Charles Schwab Investment Management Inc2025-06-30
246.2 K
Morgan Stanley - Brokerage Accounts2025-06-30
234.4 K
Ubs Asset Mgmt Americas Inc2025-06-30
234.3 K
First Trust Advisors L.p.2025-06-30
222.4 K
Fmr Inc2025-06-30
4.3 M
Blackrock Inc2025-06-30
3.8 M
View Krystal Biotech Diagnostics

Krystal Biotech Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Krystal Biotech market risk premium is the additional return an investor will receive from holding Krystal Biotech long position in a well-diversified portfolio.

Krystal Stock Against Markets

Krystal Biotech Corporate Management

Christine WilsonHead MarketingProfile
David ChienSenior DevelopmentProfile
Hubert MDSenior DevelopmentProfile
Gloria LinAccounting MangProfile
Kathryn RomanoExecutive OfficerProfile
Katherine TuminelloHR MangProfile

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.